IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Upasani et al.

Appl. No.: 10/772,445

Filed: February 6, 2004

For: Substituted Quinazolines and Analogs and the Use Thereof

Confirmation No.: 5165

Art Unit: 1615

Examiner: To be assigned

Atty. Docket: 1483.0340003/JMC/JSL

Information Disclosure Statement Under 37 C.F.R. § 1.97(b)

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Copies of the documents were cited by or submitted to the Office in an Information Disclosure Statement that complies with 37 C.F.R. § 1.98(a)-(c) in Application No. 09/654,839, filed September 1, 2000, now U.S. Patent No. 6,465,472 B1, which is relied upon for an earlier filing date under 35 U.S.C. § 120. Thus, copies of these documents are not attached. 37 C.F.R. § 1.98(d).

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates

- 2 -

Upasani *et al.* Appl. No. 10/772,445

not be prior art, and/or to prove that this information may not be enabling for the

teachings purportedly offered.

This statement should not be construed as a representation that a search has been

made, or that information more material to the examination of the present patent

application does not exist. The Examiner is specifically requested not to rely solely on

the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing date of a

first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the

enclosed PTO-1449, and indicate in the official file wrapper of this patent application

that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee

deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Jeffrey S Candgree

Jeffrey S. Lundgren

Agent for Applicants

Registration No. 51,978

Date: Aug. 20, 2004

00 New York Avenue N W

1100 New York Avenue, N.W. Washington, D.C. 20005-3934

(202) 371-2600

				9 5 0 3004				Page 1 of 10
			l mi		ATTY. DOCKET NO.	1	APPLICATION NO. 10/772,445	
	İ	FORM F	PTO-1449		1483.0340003/JMC/JS		10//12,440	
			VIEN	TA TRAUEN	Upasani et al.			
INFO	RMATION	<u>I DISC</u>	LOSURE STA	TEMENT	FILING DATE		ART UNIT	
				IIS PA	February 6, 2004		1013	
EXAMINER		DOC	UMENT	0.0.17	TENT BOODINENTO			-
INITIAL			MBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA1	3,74	18,331	06/24/1973	Cooke et al.			05/06/1971
	AB1	3,96	3,717	06/15/1976	Cooke et al.			03/10/1975
	AC1	5,28	34,957	02/08/1994	Huff			09/03/1992
	AD1	5,51	14,680	05/07/1996	Weber et al.			11/05/1993
	AE							
	AF							-
	AG							
	AH							
	Al							
	AJ							
	AK						·	
				FOREIGN	PATENT DOCUMENTS	<u> </u>		
EXAMINER		DOC	CUMENT	IORLION	TATENT BOOOMENTO			
INITIAL		NUN	MBER	DATE	COUNTRY .	CLASS	SUB-CLASS	TRANSLATION
	AL1	wo	94/13275	06/23/1993	WIPO			Yes No
	AM1							Yes No
	1,,,,							Yes
	AN1	-						No Yes
	AO1			İ				No
	AP1							Yes No
			OTHER (I	⊔ ncluding Auth	or, Title, Date, Pertine	nt Pages, e	tc.)	ı NO
	AR	1	Synthesis		plication of a Practical Benzodiazepine LY30016 ety (1995)			
	AS	1	Buchan, A. by focal iso	.M. et al., "Dela chemia," <i>Neuro</i>	iyed AMPA receptor blooreport 2:473-476, Lippin	ckade reduc acott, Willian	es cerebral infar ns & Wilkins (199	ction induced 1)
	АТ	1		n NMDA Antago	PA Antagonists: Do They onists?" Stroke Suppl. I			
EXAMINER		/Cecili	ia Jaisle/			DA	TE CONSIDERED	01/12/2008
EXAMINER: In and not conside	itial if refer red. Inclu	ence co	onsidered, whet	her or not citation i	s in conformance with MPEP (609. Draw line	through citation if no	t in conformance
·					 			

		Page 2 of 10
	ATTY. DOCKET NO. 1483.0340003/JMC/JSL	APPLICATION NO. 10/772,445
FORM PTO-1449	FIRST NAMED INVENTOR	
	Upasani et al.	
INFORMATION DISCLOSURE STATEMENT	FILING DATE	ART UNIT
	February 6, 2004	1615

U.S. PATENT DOCUMENTS									
EXAMINER INITIAL		DOC	JMENT BER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE	
	AA								
	AB								
	AC			-					
	AD								
	AE								
	AF								
	AG								
	АН								
	Al								
	AJ								
	AK								
				FOREIGN	PATENT DOCUMENTS				
EXAMINER INITIAL			CUMENT MBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
	AL							Yes No	
	АМ							Yes No	
	AN							Yes No	
	AO							Yes No	
	AP							Yes No	
			OTHER (Including Auth	or, Title, Date, Pertinent F	Pages, etc.)			
	AR	2	Choi, D.W. et al., "Glutamate Neurotoxicity in Cortical Cell Culture," <i>J. Neurosci</i> 7:357-368, Society for Neuroscience (1987)						
	AS	2	Coombs, R.V. et al., "Synthesis and Antiinflammatory Activity of 1-Alkyl-4-aryl-2(1H)-quinazolinones and Quinazolinethiones," <i>J. Med. Chem.</i> 16:1237-1245, American Chemical Society (1973)						
	АТ	2	Copani, A. et al., "Nootropic Drugs Positively Modulate ÿ-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic Acid-Sensitive Glutamate Receptors in Neuronal Cultures," <i>J. Neurochem.</i> 58:1199-1204, The International Society for Neurochemistry (1992)						
EXAMINER	1	1	/Ca	cilia .laisle/		DATE	CONSIDERED	01/12/2008	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

		Page 3 of 10
ATTY. DOCKET NO.	APPLICATION NO.	
1483.0340003/JMC/JSL	10/772,445	
FIRST NAMED INVENTOR		
Upasani et al.		
FILING DATE	ART UNIT	<u>-</u>
February 6, 2004	1615	

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT

				U.S.	PATENT DOCUMENT	rs			
EXAMINER INITIAL		DOC	JMENT BER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE	
	AA								
	AB								
-	AC		•						
	AD								
	AE						:		
	AF								
	AG								
	AH								
	Al								
	AJ								
	AK					•			
	1		 	FOREI	GN PATENT DOCUME	ENTS	1		
EXAMINER			CUMENT				OUD OLAGO	TOANIOL ATION	
INITIAL		NUI	MBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION Yes	
	AL	+						No Yes	
	AM							No Yes	
	AN							No Yes	
	AO			-				No Yes	
	AP		OTHER	(Including A	uthor Title Date Per	tinent Pages, etc.)		No	
	AR	<u>3</u>	De Sarro, G. et al., "GYKI 52466 and related 2,3-benzodiazepines as anticonvulsant agents in DBA/2 mice," Eur. J. Pharmacol. 294:411-422, Elsevier Science (1995)						
			Fetter, J. 6	et al., "Electron	Deficient Heteroaromatio	c Ammonioamidates-X	VI," Tetrahedro	on 34:2557-2563,	
	AS	3		D-0-1-vivrinster Bratis a factor attaches					
,	AT	3	Rat Focal	S.H. et al., "A C Cerebral Ische ntal Therapeuti	Pose-Response Study of Itemia," <i>J. Pharm. Exp. The</i> cs (1996)	Neuroprotection Using er. 276:1-4, American S	the AMPA Ant Society for Pha	agonist NBQX in rmacology and	
EXAMINER			/Cec	ilia Jaisle/		DATE	CONSIDERED	01/12/200	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

,		Page 4 of 10
	ATTY. DOCKET NO. 1483.0340003/JMC/JSL	APPLICATION NO. 10/772,445
FORM PTO-1449	FIRST NAMED INVENTOR	
	Upasani et al.	
INFORMATION DISCLOSURE STATEMENT	FILING DATE	ART UNIT
	February 6, 2004	1615

				U.S. PA	ATENT DOCUMENTS					
EXAMINER INITIAL		DOC NUM	UMENT BER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE		
	AA	1				02.00				
	AB	1								
	AC	1								
	AD									
	AE									
	AF	 								
	AG	1	:							
	AH	 								
	Al									
	AJ									
	AK							:		
				FOREIGN	PATENT DOCUMENTS					
EXAMINER INITIAL			CUMENT MBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION		
	AL	1						Yes No		
	AM							Yes No		
-	AN							Yes No		
<u> </u>	AO							Yes		
	AP							No Yes		
	I AF		OTHER (Including Auth	nor, Title, Date, Pertinen	t Pages, etc.)	No		
	AR	4	Haider, N., Sendai Inst	"Convenient Syn itute of Heterocy	nthesis of Cycloalkene-Fused clic Chemistry (1995)	d Phthalazinon	es," Heterocycle	es <i>41</i> :2519-2525,		
	AS	4	Houlihan, V g]quinazolir (1982)	Houlihan, W.J. et al., "Antiinflammatory Properties of 8-Aryl-5-isopropyl-2H-1,3-dioxolo[4,5-g]quinazolin-6(5H)-ones and -thiones," <i>J. Med. Chem.</i> 25:1110-1113, American Chemical Society (1982)						
	AT	4	Hunter, J.C. and L. Singh, "Role of excitatory amino acid receptors in the mediation of the nociceptive response to formalin in the rat," <i>Neurosci Lett. 174</i> :217-221, Elsevier Scientific Publishers (1994)							
EXAMINER		1	I	/Cecilia Jaisl	 e/	DATE	CONSIDERED	01/12/2008		
EXAMINER: In	itial if refe	rence co	onsidered, whe		is in conformance with MPEP 60	09. Draw line the	ough citation if no	t in conformance		
and not conside	neu. mal	are copy	or uns totti W	ar next communica	шон то гаррисант.		· ·			

		Page 5 of 10
	ATTY. DOCKET NO. 1483.0340003/JMC/JSL	APPLICATION NO. 10/772,445
FORM PTO-1449	FIRST NAMED INVENTOR	
	Upasani et al.	
INFORMATION DISCLOSURE STATEMENT	FILING DATE	ART UNIT
	February 6, 2004	1615

				U.S. PA	TENT DOCUMENTS				
EXAMINER INITIAL		DOCU	JMENT BER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE	
	AA								
	AB								
<u> </u>	AC		· -						
·	AD								
	AE								
	AF								
	AG								
	AH								
	Al	<u> </u>							
	AJ								
	AK					-			
		<u> </u>		FORFIGN	PATENT DOCUMENTS				
EXAMINER INITIAL	_		CUMENT MBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
	AL							Yes No	
	AM							Yes No	
	AN						<u> </u>	Yes	
			, <u></u>					No Yes	
	AO							No Yes	
· · · · · · · · · · · · · · · · · · ·	AP		OTHER (<u> </u> Includina Auth	or. Title. Date. Pertinent	Pages, etc.	<u> </u>	No	
	AR	<u>5</u>	Ikeda, A. et	OTHER (Including Author, Title, Date, Pertinent Pages, etc.) keda, A. et al., "Clinical Trial of Piracetam in Patients with Myoclonus: Nationwide Multiinstitution Study in Japan," <i>Movement Disorders</i> 11:691-700, Raven Press (1996)					
	AS	<u>5</u>	lwasaki, Y. newborn ra	wasaki, Y. et al., "CNQX prevents spinal motor neuron death following sciatic nerve transection in lewborn rats," <i>J. Neurosci.</i> 134:21-25, Society for Neuroscience (1995)					
	AT	<u>5</u>	Jones, B.J. Pharmacol.	et al., "The poter 93:985-993, Mad	ntial anxiolytic activity of GR3 cmillan Journals Ltd. (1988)	8032F, a 5-H	Γ3-receptor anta	agonist," <i>Br. J.</i>	
EXAMINER			/C	cecilia Jaisle/		DATE	CONSIDERED	01/12/200	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

		Page 6 of 10
	ATTY. DOCKET NO. 1483.0340003/JMC/JSL	APPLICATION NO. 10/772,445
FORM PTO-1449	FIRST NAMED INVENTOR	
	Upasani et al.	
INFORMATION DISCLOSURE STATEMENT	FILING DATE	ART UNIT
	February 6, 2004	1615

				U.S.	PATENT DOCUM	ENTS			
EXAMINER INITIAL		DOC NUM	UMENT BER	DATE	NAME	C	LASS	SUB-CLASS	FILING DATE
	AA								
	AB					- "			
	AC								
	AD		-						
	AE								
	AF								
	AG								
	AH								
	Al	<u> </u>							
	AJ								
	AK								
				FOREIG	SN PATENT DOCU	JMENTS			
EXAMINER INITIAL			CUMENT MBER	DATE	COUNTRY		CLASS	SUB-CLASS	TRANSLATION
	AL								Yes No
	АМ								Yes No
	AN					,			Yes No
	AO		· · · · · · · · · · · · · · · · · · ·						Yes No
	AP		· · · <u>-</u>						Yes No
			OTHER (Including A	uthor, Title, Date,	Pertinent Pag	ges, etc.)	140
	AR	<u>6</u>	Dihydroquii	noxaline-2,3-d	nthesis and Structure liones: Antagonists of late Receptors," <i>J. M</i> o	f N-Methyl-D-as	partate (N	IMDA) Recepto	r Glycine Sites
	AS	<u>6</u>		Larson, J. et al., "Effects of an AMPA receptor modulator on methamphetamine-induced hyperactivity in rats," <i>Brain Res.</i> 738:353-356, Elsevier/North-Holland Biomedical Press (1996)					
	AT	Le Peillet, E. et al., "The non-NMDA antagonists, NBQX and GYKI 52466, protect against cortical and striatal cell loss following transient global ischaemia in the rat," <i>Brain Res.</i> 571:115-120, Elsevier/North-Holland Biomedical Press (1992)							
EXAMINER			.L	ecilia Jaisle/			DATE	CONSIDERED	01/12/2008
			onsidered, whe	ther or not citati	ion is in conformance wi	ith MPEP 609. D			
and not conside	erea. Incli	rae cob	y of this form w	itn next commu	nication to Applicant.				

		Page 7 of 10
	ATTY. DOCKET NO.	APPLICATION NO.
	1483.0340003/JMC/JSL	10/772,445
FORM PTO-1449	FIRST NAMED INVENTOR	
	Upasani et al.	
INFORMATION DISCLOSURE STATEMENT	FILING DATE	ART UNIT
	February 6, 2004	1615

				U.S. P	ATENT DOCUMENTS	3		
EXAMINER INITIAL			UMENT IBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA							
	AB							
	AC							
	AD							
	AE		<u></u>					
	AF							
	AG							
	АН							
	Al							
	AJ							
	AK		,					
				FOREIGN	 N PATENT DOCUMEN	NTS		
EXAMINER INITIAL			CUMENT MBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL							Yes No
	АМ							Yes No
	AN							Yes No
	AO							Yes No
	AP							Yes No
	7-		OTHER (Including Aut	hor, Title, Date, Perti	nent Pages, etc	.)	
	AR	7	Lipton, S. a Disorders,"	nd P.A. Rosenb <i>N. Engl. J. Med</i>	erg, "Excitatory Amino A <i>. 330</i> :613-622, Massach	cids as a Final Co usetts Medical Soc	mmon Pathway i siety (1994)	for Neurologic
	AS	7	McDonald., J.W. et al., "Physiological and pathophysiological roles of excitatory amino acids during central nervous system development," <i>Brain Res. Rev.</i> 15:41-70, Elsevier Science (1990)					
	AT	7	Pelletier, J. Inhibitors of	C. et al., "Substi f the AMPA Rec	tuted 1,2-Dihydrophthala eptor," <i>J. Med. Chem.</i> 39	azines: Potent, Sel 9:343-346, America	ective, and Nonc an Chemical Soc	competitive ciety (1996)
EXAMINER		1	/Cecilia 、	laisle/		DATE	CONSIDERED	01/12/2008
EXAMINER: In	itial if refe	rence c	onsidered, whe	ther or not citation	is in conformance with MPI			
and not conside	rea. Incl	ine cob	y of this form wi	ur next communic	ation to Applicant.			

		Page 8 of	10
	ATTY. DOCKET NO. 1483.0340003/JMC/JSL	APPLICATION NO. 10/772,445	
FORM PTO-1449	FIRST NAMED INVENTOR		
	Upasani et al.		
INFORMATION DISCLOSURE STATEMENT	FILING DATE	ART UNIT	
	February 6, 2004	1615	


				U.S. F	PATENT DOCUMENT	<u>s</u>		
EXAMINER			UMENT					
INITIAL	_	NUM	IBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA							
	AB	 						
	1,.0							
	AC							
	<u> </u>	ļ						
	AD							
	AE	 					 	
	125						Ì	
	AF	<u> </u>				·····		
	AG							
	 							
	AH							
	AI	 					<u> </u>	
	1							
	AJ							
	1						ļ	
	AK							
		1		EODEIG	N PATENT DOCUME	NTC	1	<u> </u>
EXAMINER	1			FUNEIG	N PATENT DOCUME	N 1 3	T	
INITIAL		DO	CUMENT	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
IIIIIAL			MBER			0.5.00		
								Yes
	AL							No
								Yes
	AM	_					-	No Yes
	AN]	No
	1							Yes
	AO							No
								Yes
	AP		OT: 150				<u>,L</u>	No
		1	OTHER	Including Au	thor, Title, Date, Pert	inent Pages, etc.)	
	AR	8	Capsaicin-	Evoked Allodyn	sic Effects of AMPA/Kain ia and Hyperalgesia But .14, Society of Neuroscie	Not Pain Sensations	s In Normal Skir	: Reduction of n," <i>Soc. Neuroci</i>
	AS	8	Schoepp, D. et al., "Pharmacological and functional characteristics of metabotropic excitatory amino acid receptors," <i>Trends Pharm Sci</i> 11:508-515, Elsevier in Association with the International Union of Pharmacology (1990)					
	AT _.	8			3-Dihydroxy-6-nitro-7-su ce 247:571-574, America	an Association for th	e Advancement	of Science
EXAMINER		<u> </u>	// '''	1-1-1-7	,_,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	DATE	CONSIDERED	04/40/0000
			/Cecilia					
EXAMINER: In	itial if refe	rence c	onsidered, whe	ther or not citatio	n is in conformance with MF	PEP 609. Draw line the	ough citation if no	t in conformance
and not conside	eu. Indi	ue cop	y or uns form W	iui riexi communi	cation to Applicant.			

		Page 9 of 10
	ATTY. DOCKET NO. 1483.0340003/JMC/JSL	APPLICATION NO. 10/772,445
FORM PTO-1449	FIRST NAMED INVENTOR	
	Upasani et al	
INFORMATION DISCLOSURE STATEMENT	FILING DATE	ART UNIT
	February 6, 2004	1615

				U.S. P	ATENT DOCUMENT	rs			
EXAMINER			UMENT	DATE	NIA NAIT	CLASS	CUID C		FILING DATE
INITIAL	AA	NUM	BEK	DATE	NAME	CLASS	SUB-C	LASS	FILING DATE
			,						
	AB								
	AC								
	AD								
		ļ							
	AE								
	AF								
	AG								· ·
	АН								· · · · ·
	Al								11.6 1 18
	AJ								
	AK		<u>-</u>			-			
				FORFION	L DATENT BOOKING	-			
EXAMINER		- -		FOREIGN	I PATENT DOCUME	:NIS			
INITIAL			CUMENT MBER	DATE	COUNTRY	CLAS	S SUB-C	LASS TI	RANSLATION
	AL	110.	VIDEI (-	Yes No
									Yes
	AM								No Yes
	AN								No Yes
	AO		***						No_
	AP								Yes No
			OTHER (ncluding Aut	hor, Title, Date, Per	tinent Pages, e	etc.)		
	AR	9	Sheardown ischaemia,	, M.J. et al., "AN even when dela	IPA, but not NMDA, rec yed 24 h," Eur. J. Phan	ceptor antagonisr macol. 236:347-3	m is neuropro 353, Elsevier	otective in Science (n gerbil global (1993)
	AS	Staubli, U. et al., "Facilitation of glutamate receptors enhances memory," <i>Proc. Natl. Acad. Sci. USA</i> 91:777-781, National Academy of Sciences (1994)						d. Sci. USA	
	AT	9	Thomas, R. Blackwell S	J., "Excitatory A cience (1995)	mino Acids in Health a	nd Disease," <i>J. A</i>	m. Geriatr. S	Soc. 43:12	279-1289,
EXAMINER	I	/Cer	ilia Jaisle/			DA	TE CONSID	ERED (01/12/2008
EXAMINER: In	itial if refe			ther or not citation	is in conformance with Mi	PEP 609. Draw line	e through citat		
and not conside	ered. Inclu	ide copy	of this form wi	th next communic	ation to Applicant.				

			Page 10 of 10
	ATTY. DOCKET NO. 1483.0340003/JMC/JSL	APPLICATION NO. 10/772,445	
FORM PTO-1449	FIRST NAMED INVENTOR		
	Upasani et al.		
INFORMATION DISCLOSURE STATEMENT	FILING DATE	ART UNIT	
	February 6, 2004	1615	

				U.S	PATENT DOCUM	IENTS			
EXAMINER INITIAL		DOC NUM	UMENT BER	DATE	NAME		CLASS	SUB-CLASS	FILING DATE
	AA	1					02.00	000 00 100	, , , , , , , , , , , , , , , , , , , ,
	AB								
	AC	-							
	AD								
	AE								
	AF	-							
	AG								
	AH	- -	·						
	AI								
	AJ			-					
	AK								
				FORFI	ON DATENT DOO				
EXAMINER				FUREI	GN PATENT DOC	UMENIS	T	T	r
INITIAL			CUMENT MBER	DATE	COUNTRY		CLASS	SUB-CLASS	TRANSLATION
	AL								Yes No
	AM								Yes No
	AN								Yes No
	AO								Yes
									No Yes
	AP	_ .	OTHER	│ (Including A	uthor, Title, Date,	Pertinent Pa	│ ages, etc.)	No
	AR	10	Woodward	l, R.M. et al., " ediones with I	In Vitro Pharmacolog High Affinity and Sele 581, American Socie	y of ACEA-10:	21 and ACE	A-1031: Syster	Glycine Sites."
	AS	10	Wrathall, J.R. et al., "Amelioration of Functional Deficits from Spinal Cord Trauma with Systemically Administered NBQX, an Antagonist of Non-N-Methyl-D-Aspartate receptors," <i>Exp. Neurology 137</i> :1126, Academic Press (1996)						Systemically irology 137:119-
	AT								
EXAMINER		/Cecili	ia Jaisle/				DATE	CONSIDERED	01/12/2008
EXAMINER: In	itial if refe	rence co	onsidered, whe	ether or not citat	ion is in conformance w nication to Applicant.	rith MPEP 609.			
Land Hot Conside	ijou. IIIUlu	ac wpy	OI UIIS IOIIII W	not Heat Commu	meauon to Applicant.				



Robert Greene Sterne Edward J. Kessler Jorge A. Goldstein David K.S. Comwell Robert W. Esmond Tracy-Gene G. Durkin Michael B. Ray Robert E. Sokohl Eric K. Steffe Michael Q. Lee Steven R. Ludwig John M. Covert Linda E. Alcom Robert C. Millonig Lawrence B. Bugaisky Donald J. Featherston Michael V. Messinger Judith U. Kim Timothy J. Shea, Jr. Patrick E. Garrett Jeffrey T. Helvey Heidi L. Kraus Albert L. Ferro* Donald R. Banowit Peter A. Jackman Teresa U. Medler Jeffrey S. Weaver Kendrick P. Patterson Vincent L. Capuano Eldora Ellison Floyd Thomas C. Fiala Brian J. Del Buono Virgil Lee Beaston Theodore A. Wood Elizabeth J. Haanes Joseph S. Ostroff Frank R. Cottingham Christine M. Lhulier Rae Lynn P. Guest George S. Bardmesser Daniel A. Klein* Jason D. Eisenberg Michael D. Specht Andrea J. Kamage Tracy L. Muller* LuAnne M. DeSantis Ann E. Summerfield Aric W. Ledford* Helene C. Carlson Timothy A. Doyle* Gaby L. Longsworth Lori A. Gordon* Nicole D. Dretar*

Ted J. Ebersole
Jyoti C. Iyer*
Laura A. Vogel

<u>Registered Pate</u>
Karen R. Markt
Nancy J. Leith
Matthew J. Doo
Aaron L. Schwa
Katrina Yujian I
Bryan L. Skelto

Registered Patent Agents-Karen R. Markowicz Nancy J. Leith Matthew J. Dowd Aaron L. Schwartz Katrina Yujian Pei Quach Bryan L. Skelton Robert A. Schwartzman Teresa A. Colella Jeffrey S. Lundgren Victoria S. Rutherford Michelle K. Holoubek Robert H. DeSelms Simon J. Elliott Julie A. Heider Mita Mukherjee Scott M. Woodhouse Michael G. Penn Christopher J. Walsh

Of Counsel Kenneth C. Bass III Evan R. Smith Marvin C. Guthrie

*Admitted only in Maryland *Admitted only in Virginia •Practice Limited to Federal Agencies

August 20, 2004

WRITER'S DIRECT NUMBER: (202) 772-8787 INTERNET ADDRESS: LUNDGREN@SKGF.COM

Art Unit 1615

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Re:

U.S. Utility Patent Application

Application No. 10/772,445; Filed: February 6, 2004

For: Substituted Quinazolines and Analogs and the Use Thereof

Inventors: Upasani et al.

Our Ref:

1483.0340003/JMC/JSL

Sir:

Transmitted herewith for appropriate action are the following documents:

- 1. Information Disclosure Statement;
- 2. Form PTO-1449 citing documents on Information Disclosure Statement (AA1-AD1, AL1, AR1-AT1, AR2-AT2, AR3-AT3, AR4-AT4, AR5-AT5, AR6-AT6, AR7-AT7, AR8-AT8, AR9-AT9, AR10, AS10);
- 3. First Supplemental Information Disclosure Statement;
- 4. Form PTO-1449 citing documents on First Supplemental Form PTO-1449 citing documents (AE1-AH1, AM1-AP1, AT10, AL2);
- 5. Second Supplemental Information Disclosure Statement;
- 6. Form PTO-1449 citing documents on Second Supplemental Form PTO-1449 citing documents (AM2, and AR11-AT11); and
- 7. Return Postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Sterne, Kessler, Goldstein & Fox PLLC. : 1100 New York Avenue, NW : Washington, DC 20005 : 202.371.2600 f 202.371.2540 : www.skgf.com

Commissioner for Patents August 20, 2004 Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Jeffrey S. Lundgren
Agent for Applicants
Registration No. 51,978

JSL/asl Enclosures

301903v1

Sterne, Kessler, Goldstein & Fox PLLC. : 1100 New York Avenue, NW : Washington, DC 20005 : 202.371.2600 f 202.371.2540 : www.skgf.com

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Upasani et al.

Appl. No.: 10/772,445

Filed: February 6, 2004

For: Substituted Quinazolines and Analogs and the Use Thereof

Confirmation No.: 5165

Art Unit: 1615

Examiner: To be assigned

Atty. Docket: 1483.0340003/JMC/JSL

First Supplemental Information Disclosure Statement

Under 37 C.F.R. § 1.97(b)

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering of this First Supplemental Information Disclosure Statement is a continuation of Applicants' Information Disclosure Statement filed herewith, in connection with the above-captioned application.

Copies of documents AE1 to AH1, AM1 to AL2, and AT10 were cited by or submitted to the Office in an Information Disclosure Statement that complies with 37 C.F.R. § 1.98(a)-(c) in Application No. 09/654,839, filed September 1, 2000, now U.S. Patent No. 6,465,472 B1, which is relied upon for an earlier filing date under 35 U.S.C. § 120. Thus, copies of these documents are not attached. 37 C.F.R. § 1.98(d).

In accordance with 37 C.F.R. § 1.98(a)(3), Applicants' undersigned representative submits the following discussion of the relevance of the non-English language document AN1 cited on Form PTO 1449:

Document AN1 is in a foreign language. An English language abstract of document AN1 is attached as document AT10.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Jeffrey S. Lundgren
Agent for Applicants
Registration No. 51,978

Date: Aug. 20, 200

1100 New York Avenue, N.W. Washington, D.C. 20005-3934

(202) 371-2600

								Page 1 of 2		
	-		TO 1440		ATTY. DOCKET NO. APPLICATION NO. 1483.0340003/JMC/JSL 10/772,445					
	Г	-ORIVI P	TO-1449		FIRST NAMED INVENTOR Upasani et al.					
FIRST SUPF				DISCLOSURE	FILING DATE ART UNIT					
		STATE	MENT		February 6, 2004 1516					
EVALUED	-	1000		U.S. PA	TENT DOCUMENTS					
EXAMINER INITIAL		NUM	UMENT BER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE		
	AA	1			1000	02.00	000 02 .00	1		
	_									
	AB							,		
	AC									
	AD									
	AE1	3,75	9,920	09/18/1973	Linder et al.			06/24/1971		
	AF1	3,85	6,960	12/24/1974	Cooke et al.			04/13/1973		
	AG1	4,22	4,328	09/23/1980	Takesue			04/11/1979		
	AH1	5,65	0,410	07/22/1997	Sohda et al.			04/17/1995		
	Al									
	AJ	i								
	AK									
				FOREIGN	PATENT DOCUMENT	S				
EXAMINER			UMENT	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION		
INITIAL	 	NUM	BEK	DATE	COUNTRY	CLASS	SUB-CLASS	Yes		
	AL							No		
								X Yes		
	AM1	DE 2	2 058 722	06/09/1971	Germany			No		
	AN1	DE 2	2 307 808	08/30/1973	Germany			Yes X No		
	AO1	GB ·	1341401	12/19/1993	Great Britain			Yes		
	AP1	ED	567 107 A1	10/27/1003	Europe		,	Yes No		
		, Li	OTHER (II	cluding Author	or, Title, Date, Pertine	ent Pages, e	tc.)	1 110		
	AR									
	AS									
			Dialog File	351. Accession	n No. 1973-41080U/19	7329, Derwe	nt WPI English la	anguage		
	AT	<u>10</u>	abstract for	DE 2 307 808	(Document AN1)		· · · · · · · · · · · · · · · · · · ·			
EVALUATED			L			154	TE CONCIDERE			
EXAMINER				ia Jaisle/			TE CONSIDERED			
				ner or not citation is h next communicat	s in conformance with MPEF	609. Draw line	through citation if no	ot in conformance		
Cario nor consider	ou, indu	co oopy	C. SING TOTAL WILL							

285000_1.DOC SKGF Rev. 12/03/03

		Page 2 of 2
	ATTY. DOCKET NO. 1483.0340003/JMC/JSL	APPLICATION NO. 10/772,445
FORM PTO-1449	FIRST NAMED INVENTOR	
	Upasani et al.	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE	FILING DATE	ART UNIT
STATEMENT	February 6, 2004	1516

			U.S. P	ATENT DOCUMENTS	3		
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
INITIAL	AA	NOWIDER	DATE	IAVIAIC	CLASS_	30D-CLASS	TILING DATE
	AB	 					
	AC						
	AD						
	AE						
	AF						
	AG					<u> </u>	
	AH						
	Al						
	AJ						
	AK						
EXAMINER	1		FOREIGN	PATENT DOCUME	NTS	1	
INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	
	AL2	EP 0 634 169 A1	01/18/1995	Europe			Yes No
	АМ						Yes No
	AN						Yes No
							Yes
	AO						No Yes
-	AP	OTHER (I	Including Aut	 hor, Title, Date, Perti	inent Pages, etc.	1	No
		OTTLK (I	including Aut	nor, Title, Date, Fert	ment rages, etc.	·1	
	AR						
	AS						
							- ··· - ···
1	AT						
EXAMINER		/Cecilia Jaisl			DATE	CONSIDERED	01/12/2008
		erence considered, whe	ther or not citation	is in conformance with MP	PEP 609. Draw line th	rough citation if no	ot in conformance
and not conside	ered. Incl	ude copy of this form wi	th next communic	ation to Applicant.	<u> </u>		



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Confirmation No.: 5165

Upasani et al.

Art Unit: 1615

Appl. No.: 10/772,445

Examiner: To be assigned

Filed: February 6, 2004

For: Substituted Quinazolines and Analogs and the Use Thereof

Atty. Docket: 1483.0340003/JMC/JSL

Second Supplemental Information Disclosure Statement

Under 37 C.F.R. § 1.97(b)

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering of this Second Supplemental Information Disclosure Statement is a continuation of Applicants' First Information Disclosure Statement filed herewith, in connection with the above-captioned application.

Copies of the documents were cited by or submitted to the Office in an Information Disclosure Statement that complies with 37 C.F.R. § 1.98(a)-(c) in Application No. 10/219,755, filed August 16, 2002, now U.S. Patent No. 6,765,006 B2, which is relied upon for an earlier filing date under 35 U.S.C. § 120. Thus, copies of these documents are not attached. 37 C.F.R. § 1.98(d).

In accordance with 37 C.F.R. § 1.98(a)(3), Applicants' undersigned representative submits the following discussion of the relevance of the non-English language document AM2 cited on Form PTO 1449:

Document AM2 is in a foreign language. An English language translation of document AM2 is attached as document AR11.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Jeffry S. Lundgren
Agent for Applicants
Registration No. 51,978

Date: <u>Aug. 20, 2004</u>

1100 New York Avenue, N.W. Washington, D.C. 20005-3934 (202) 371-2600

			/	LIPER				
• • •	-3			Me s o sook sign	ATTY. DOCKET N 1483.0340003/JM		APPLICATION NO. 10/772,445	Page 1 of 1
	F	ORM P	TO-1449		FIRST NAMED INVE			
FORM PTO-1449 SECOND SUPPLEMENTAL INFORMATION OF THE SURE				KAISBODE URE	Upasani et al. FILING DATE ART UNIT			
<u> </u>		STATE	MENT	11-21-01-12	February 6, 2004		1516	
				U.S. PA	TENT DOCUMENT	ΓS		
EXAMINER INITIAL		DOC	UMENT	DATE	NAME	CLASS	SUB-CLASS	EII INO DATE
INITIAL	AA	INOIN	BER	DATE	INAIVIE	CLASS	30B-CLASS	FILING DATE
	AB							
	AC	+	·					
	^0							
	AD							
	AE	- -		1				
	~~		_					
	AF							
	AG	+ -					····	
	^0			}		ļ		
	AH							
	Al				-			
	^'							
	AJ							
***	AK						· · -	-
		<u>'</u>		FOREIGN F	PATENT DOCUME	ENTS	•	
EXAMINER INITIAL		DOC	UMENT	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
INTIAL	İ	INCIV	BEIX	DAIL	COONTIC	CEASC	S SOB-CLASS	Yes
	AL	ļ						No
	AM2	100	51-8287	01/23/1976	Japan			X Yes
	AIVIZ	1 51 -	331-0207	01/23/19/0	Japan			Yes
	AN	ļ						No
	AO							Yes No
	1							Yes
	AP				<u> </u>			No
			OTHER (I	ncluding Autho	or, Title, Date, Per	tinent Pages, e	etc.)	
			English lan	guage translatio	on of Japanese Un	examined Pater	nt Application No.	JP S51-8287
50000000000000000000000000000000000000	40036485000000			http://doctor/contraction/contractor	Montoularesi Massastro de estra sensa sens	belack (Digital Section of State Section of	000000000000000000000000000000000000000	000000000000000000000000000000000000000
								
			Yamamoto	, M., et al., "Qui	nazolin-2-ones froi	m 3,4-dihydroqu	inazolin-2-ones,"	Chem. Abstr.
000000000000000000000000000000000000000	ÄS	<u> 11</u>	784.380, Ab	stract No. 1602	77m, American Ch	remical Society	(1978)	000000000000000000000000000000000000000
			Supplement	stam, Double Lin	oneen Coarsh Don	and for Europe	- Annlination No	ED00044063
	 	77		itary Partial Eur ich 2, 1999	opean Search Rep	port for Europea	n Application No.	ELAAA11002
	AT	11	, mod on Ma					
EXAMINER			/00	cilia Jaisle/		DA	TE CONSIDERED	01/10/0000
	-1:67				In			U 1/12/2008
				her or not citation is h next communicati	in conformance with M on to Applicant.	nrer ous. Draw line	e inrough ditation if no	oun conformance

285033_1.DOC SKGF Rev. 12/03/03